Compile Data Set for Download or QSAR
Report error Found 195 Enz. Inhib. hit(s) with all data for entry = 11350
TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM609011(US11702409, Example 80a | US11702409, Example 80b)
Affinity DataIC50: 8nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM50579992(CHEMBL5080264 | US11702409, Example 69b)
Affinity DataIC50: 9nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608941(US11702409, Example 43a | US11702409, Example 43b)
Affinity DataIC50: 10nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608859(US11702409, Example 16a | US11702409, Example 16b)
Affinity DataIC50: 11nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608937(US11702409, Example 41a | US11702409, Example 41b ...)
Affinity DataIC50: 11nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608939(US11702409, Example 42a | US11702409, Example 42b)
Affinity DataIC50: 12nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM609015(US11702409, Example 82a | US11702409, Example 82b)
Affinity DataIC50: 12nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608864(US11702409, Example 17a | US11702409, Example 17b)
Affinity DataIC50: 13nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM50579987(CHEMBL5083497 | US11702409, Example 18b)
Affinity DataIC50: 14nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM609006(US11702409, Example 76a | US11702409, Example 76b)
Affinity DataIC50: 15nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608857(US11702409, Example 15a | US11702409, Example 15b)
Affinity DataIC50: 16nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM50579985(Jdq 443 | Jdq-443 | Nvp-jdq-443 | JDQ443 | JDQ-443...)
Affinity DataIC50: 17nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608852(US11702409, Example 13a | US11702409, Example 13b)
Affinity DataIC50: 18nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM609017(US11702409, Example 83a | US11702409, Example 83b)
Affinity DataIC50: 18nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608943(US11702409, Example 44a | US11702409, Example 44b)
Affinity DataIC50: 19nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608876(US11702409, Example 22a | US11702409, Example 22b)
Affinity DataIC50: 23nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608850(US11702409, Example 12a | US11702409, Example 12b)
Affinity DataIC50: 24nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM50579990(CHEMBL5081366 | US11702409, Example 52b)
Affinity DataIC50: 26nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM50579988(CHEMBL5075960 | US11702409, Example 35b)
Affinity DataIC50: 27nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608976(US11702409, Example 61a | US11702409, Example 61b)
Affinity DataIC50: 27nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608994(US11702409, Example 70a | US11702409, Example 70b)
Affinity DataIC50: 30nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608933(US11702409, Example 39a | US11702409, Example 39b)
Affinity DataIC50: 32nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608968(US11702409, Example 57a | US11702409, Example 57b)
Affinity DataIC50: 33nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608955(US11702409, Example 50a | US11702409, Example 50b)
Affinity DataIC50: 35nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM50579991(CHEMBL5078639 | US11702409, Example 56b)
Affinity DataIC50: 38nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608882(US11702409, Example 25a | US11702409, Example 25b)
Affinity DataIC50: 41nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608832(US11702409, Example 5a | US11702409, Example 5b)
Affinity DataIC50: 43nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608886(US11702409, Example 26a | 1-{6-[(4M)-4-(5-Chloro-6...)
Affinity DataIC50: 43nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608949(US11702409, Example 47a | US11702409, Example 47b)
Affinity DataIC50: 43nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608978(US11702409, Example 62a | US11702409, Example 62b)
Affinity DataIC50: 45nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608984(US11702409, Example 65a | US11702409, Example 65b)
Affinity DataIC50: 46nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608952(US11702409, Example 48)
Affinity DataIC50: 49nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608974(US11702409, Example 60a | US11702409, Example 60b)
Affinity DataIC50: 51nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608982(US11702409, Example 64a | US11702409, Example 64b)
Affinity DataIC50: 55nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608990(US11702409, Example 68a | US11702409, Example 68b)
Affinity DataIC50: 59nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608872(US11702409, Example 21a | US11702409, Example 21b)
Affinity DataIC50: 60nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608970(US11702409, Example 58a | US11702409, Example 58b)
Affinity DataIC50: 64nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608838(US11702409, Example 8a | US11702409, Example 8b)
Affinity DataIC50: 66nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608880(US11702409, Example 24a | US11702409, Example 24b)
Affinity DataIC50: 71nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608980(US11702409, Example 63a | US11702409, Example 63b)
Affinity DataIC50: 88nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM609010(US11702409, Example 79a)
Affinity DataIC50: 92nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM50579986(CHEMBL5076213 | US11702409, Example 2b)
Affinity DataIC50: 93nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608935(US11702409, Example 40a | US11702409, Example 40b)
Affinity DataIC50: 99nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608996(US11702409, Example 71a | US11702409, Example 71b)
Affinity DataIC50: 101nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608896(US11702409, Example 30a | US11702409, Example 30b)
Affinity DataIC50: 103nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM609013(US11702409, Example 81a | US11702409, Example 81b)
Affinity DataIC50: 110nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608928(US11702409, Example 37a | US11702409, Example 37b)
Affinity DataIC50: 112nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608870(US11702409, Example 20a | US11702409, Example 20b)
Affinity DataIC50: 148nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608836(US11702409, Example 7a | US11702409, Example 7b)
Affinity DataIC50: 162nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM608972(US11702409, Example 59a | US11702409, Example 59b)
Affinity DataIC50: 173nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
Go to US Patent

Displayed 1 to 50 (of 195 total ) | Next | Last >>
Jump to: